Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanobiotix, a nanomedicine company, has announced that it will collaborate with, among others, Philips, Erasmus University Medical Center, the University of Munster and the University of London in a four-year project known as 'SonoDrugs' - which aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cardiovascular disease and cancer, the first- and second-leading causes, respectively, of death in the EU.
Subscribe to our email newsletter
The SonoDrugs collaboration aims to develop new materials and drug nanocarrier systems for improved localized drug delivery that can be activated by ultrasound waves. Magnetic resonance imaging (MRI) and ultrasound will be used to visualize and guide the drug-delivery process and also to provide immediate feedback on the success of the procedure, enabling adjustment and fine-tuning of the therapeutic intervention.
The SonoDrugs project includes a total of 15 industry partners, university medical centers, and academic institutions from throughout the EU and has a budget of $19 million.
Laurent Levy, president and CEO of Nanobiotix, said: For Nanobiotix, collaboration with SonoDrugs valorizes the company’s know-how in MRI contrast agents and activated therapies as well as nanoparticle design and manufacturing.
Furthermore, the number of applications and associated markets for Nanobiotix products will be increased by this collaboration. We are extremely pleased to be a part of this groundbreaking effort to enhance treatment of cancer and cardiovascular disease.